GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor
Published 10/17/18 by GEn1E Lifesciences, Inc. Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress syndrome therapy PALO ALTO, Calif., Oct. 17, …
